Effectiveness of Mepolizumab In Treating Chronic Obstructive Pulmonary Disease

Short Title: REALITI-C

Enrollment Status: Recruiting

Specialty Area: Pulmonology

Condition Studied: Chronic Obstructive Pulmonary Disease (COPD)

Age Groups: Adult; Older Adult

Phase: Not Applicable

Study Information

Summary / Purpose

To generate insights into the real-world effectiveness of mepolizumab in patients with chronic obstructive pulmonary disease.

Study Type: Observational

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 40+ years of age
Diagnosed with Chronic Obstructive Pulmonary Disease (COPD) for at least 12 months
Newly prescribed mepolizumab (NUCALA®) for treating COPD

What's Involved

Participation in the study will include:

Sharing health-related data collected from 12 months before you join the

study, at the time when you start mepolizumab (NUCALA®), and at

approximately 6, 12, 24, and 36 months after starting mepolizumab (NUCALA®)

Questionnaires about your health and quality-of-life

Principal Investigator

Farah Madhani-Lovely, MD

Critical Care Medicine

A Member of

(775) 982–5000

Renown Medical Group – Pulmonary Medicine

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews